Progress in intravenous iron treatment

Joannes JM Marx

doi:10.1055/s-0031-1296298

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2010; 60(6): 341-344
DOI: 10.1055/s-0031-1296298

Ferric Carboxymaltose

Editio Cantor Verlag Aulendorf (Germany)

Progress in intravenous iron treatment

Introduction

Joannes JM Marx MD, PhD

Eijkman Winkler Institute, Utrecht University Medical Centre, Utrecht, The Netherlands Email: marx@planet.nl

› Author Affiliations

Abstract

Full Text

References

References
1 Nissim JA. Intravenous administration of iron. Lancet. 1947; 2: 49-51
2 Nissim JA, Robson JM. Preparation and standardization of saccharated iron oxide for intra venous administration. Lancet. 1949; 1 (6556) 686-9
3 Olsson KS. Availability of iron sorbitol for hemoglobin formation as studied with phlebotomy. Acta Med Scand. 1972; 192 (6) 551-8
4 Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243 (17) 1726-31
5 Coleman DH, Stevens Jr AR, Finch CA. The treatment of iron deficiency anemia. Blood. 1955; 10 (6) 567-81
6 Imferon, Iron-dextran injection B.P., Iron Dextran USP. In: Clinical medicine, 2nd edition. Fisons Ltd; 1968 (reprinted 1974).
7 Garby L, Sjolin S. Some observations on the distribution kinetics of radioactive colloidal iron (Imferon and ferric hydroxide). Acta Med Scand. 1957; 157 (4) 319-25
8 Varde KN. Treatment of 300 cases of iron deficiency of pregnancy by total dose infusion of iron-dextran complex. J Obstet Gynaecol Br Commonw. 1964; 71: 919-22
9 Clay B et al. Reactions to Total dose intravenous infusion of iron dextran (Imferon). Br Med J. 1965; 1 (5426) 29-31
10 Hart GD, Soots M. An anaphylactic reaction complicating total dose infusion therapy of iron deficiency. Appl Ther. 1969; 11 (12) 645-6
11 Zipf Jr. RE. Fatal anaphylaxis after intravenous iron dextran. J Forensic Sci. 1975; 20 (2) 326-33
12 Maier C. [Jectofer][a new preparation for intramuscular iron injection.]. Schweiz Med Wochenschr. 1964; 94: 659-61
13 Kooistra MP et al. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol. 1991; 79 (4) 634-9
14 Kooistra MP et al. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13 (1) 82-8
15 Cavill I et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin. 2006; 22 (4) 731-7
16 Besarab A, Horl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009; 14 (Suppl 1) 22-23
17 KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target Am J Kidney Dis. 2007; 50 (3) 471-530
18 Auerbach M et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004; 22 (7) 1301-7
19 Bastit L et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008; 26 (10) 1611-8
20 Breymann C et al. Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest. 2000; 30 (2) 154-61
21 Breymann C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101 (1) 67-73
22 Van Wyck DB et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49 (12) 2719-28
23 Munoz M, Gomez-Ramirez S, Garcia-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol. 2009; 15 (37) 4666-74
24 Kulnigg S et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103 (5) 1182-92
25 Bolger AP et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006; 48 (6) 1225-7
26 Zheng S et al. Iron deficiency anemia and iron losses after renal transplantation. Transpl Int. 2009; 22 (4) 434-40
27 Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369 (9572) 1502-4
28 Charytan C et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004; 96 (2) c63-6
29 Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992; 42 (12) 1439-52
30 Kooistra MP et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron sac-charate infusion. Eur J Clin Invest. 2002; 32 (Suppl 1) 36-41
31 Rooyakkers TM et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002; 32 (Suppl 1) 9-16
32 Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38 (5) 988-91
33 Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006; 1 (Suppl 1) S19-23
34 Lim PS et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999; 14 (11) 2680-7
35 Kartikasari AE et al. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler Thromb Vasc Biol. 2004; 24 (12) 2257-62
36 Kartikasari AE et al. Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J. 2006; 20 (2) 353-5
37 Kartikasari AE et al. Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration: Iron and monocyte-endothelial cell interactions. Atherosclerosis. 2009; 205 (2) 369-75
38 Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009; 69 (6) 739-56
39 Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert. 2009; 23: 11-6
40 Esposito BP et al. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002; 32 (Suppl 1) 42-9
41 Driss F et al. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients. Nephron Clin Pract. 2005; 99 (3) c63-7
42 van der DL A et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation. 2006; 113 (16) 1942-9